Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Regenxbio's Return On Capital Employed Overview

Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.22 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 126.09%, resulting in a loss of $76.72 million. Regenxbio earned $294.02 million, and sales totaled $398.65 million in Q4.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.